HilleVax, Inc. (HLVX)

Market Cap	90.67M
Revenue (ttm)	n/a
Net Income (ttm)	-156.27M
Shares Out	47.72M
EPS (ttm)	-3.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,967
Open	1.870
Previous Close	1.870
Day's Range	1.833 - 1.920
52-Week Range	1.550 - 20.220
Beta	0.77
Analysts	Hold
Price Target	2.33 (+22.63%)
Earnings Date	Nov 11, 2024

About HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2022
• Employees: 90
• Stock Exchange: NASDAQ
• Ticker Symbol: HLVX
• Website: https://www.hillevax.com

Analyst Forecast

According to 5 analysts, the average rating for HLVX stock is "Hold." The 12-month stock price forecast is $2.33, which is an increase of 22.63% from the latest price.

Price Target

$2.33

(22.63% upside)

Analyst Consensus: Hold